Scott Bell

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1749768/publications.pdf

Version: 2024-02-01

254 papers	16,996 citations	22153 59 h-index	17105 122 g-index
273 all docs	273 docs citations	273 times ranked	15616 citing authors

#	Article	IF	Citations
1	A CFTR Potentiator in Patients with Cystic Fibrosis and theG551DMutation. New England Journal of Medicine, 2011, 365, 1663-1672.	27.0	1,920
2	Lumacaftorâ€"Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508delCFTR. New England Journal of Medicine, 2015, 373, 220-231.	27.0	1,308
3	The future of cystic fibrosis care: a global perspective. Lancet Respiratory Medicine,the, 2020, 8, 65-124.	10.7	573
4	ECFS best practice guidelines: the 2018 revision. Journal of Cystic Fibrosis, 2018, 17, 153-178.	0.7	521
5	Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium. Science, 2016, 354, 751-757.	12.6	462
6	Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax, 2002, 57, 212-216.	5.6	459
7	Control of Confounding and Reporting of Results in Causal Inference Studies. Guidance for Authors from Editors of Respiratory, Sleep, and Critical Care Journals. Annals of the American Thoracic Society, 2019, 16, 22-28.	3.2	458
8	European Cystic Fibrosis Society Standards of Care: Best Practice guidelines. Journal of Cystic Fibrosis, 2014, 13, S23-S42.	0.7	438
9	Treatment of lung infection in patients with cystic fibrosis: Current and future strategies. Journal of Cystic Fibrosis, 2012, 11, 461-479.	0.7	421
10	Cystic fibrosis. Nature Reviews Disease Primers, 2015, 1, 15010.	30.5	403
11	A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respiratory Medicine,the, 2014, 2, 527-538.	10.7	372
12	Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 10391-10396.	7.1	307
13	Genetic Modifiers of Liver Disease in Cystic Fibrosis. JAMA - Journal of the American Medical Association, 2009, 302, 1076.	7.4	256
14	Future trends in cystic fibrosis demography in 34 European countries. European Respiratory Journal, 2015, 46, 133-141.	6.7	238
15	Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial. Lancet, The, 2005, 366, 463-471.	13.7	225
16	The Rise of Non-Tuberculosis Mycobacterial Lung Disease. Frontiers in Immunology, 2020, 11, 303.	4.8	219
17	Antibiotic Susceptibilities of Pseudomonas aeruginosa Isolates Derived from Patients with Cystic Fibrosis under Aerobic, Anaerobic, and Biofilm Conditions. Journal of Clinical Microbiology, 2005, 43, 5085-5090.	3.9	203
18	Development and Reporting of Prediction Models: Guidance for Authors From Editors of Respiratory, Sleep, and Critical Care Journals. Critical Care Medicine, 2020, 48, 623-633.	0.9	188

#	Article	IF	Citations
19	Neutrophils in cystic fibrosis. Thorax, 2008, 64, 81-88.	5.6	176
20	Ex vivo monitoring of human cytomegalovirus-specific CD8+ T-cell responses using QuantiFERONï¿½-CMV. Transplant Infectious Disease, 2007, 9, 165-170.	1.7	154
21	Burkholderia stagnalis sp. nov. and Burkholderia territorii sp. nov., two novel Burkholderia cepacia complex species from environmental and human sources. International Journal of Systematic and Evolutionary Microbiology, 2015, 65, 2265-2271.	1.7	149
22	Clinical utilization of genomics data produced by the international Pseudomonas aeruginosa consortium. Frontiers in Microbiology, 2015, 6, 1036.	3.5	144
23	New pharmacological approaches for cystic fibrosis: Promises, progress, pitfalls. , 2015, 145, 19-34.		140
24	Bone mineral density in Australian children, adolescents and adults with cystic fibrosis: a controlled cross sectional study. Thorax, 2004, 59, 149-155.	5.6	138
25	Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand Thoracic Society of Australia and New Zealand guidelines. Medical Journal of Australia, 2015, 202, 21-23.	1.7	133
26	Cough-generated aerosols of Pseudomonas aeruginosa and other Gram-negative bacteria from patients with cystic fibrosis. Thorax, 2009, 64, 926-931.	5.6	122
27	Within-Host Evolution of Burkholderia pseudomallei over a Twelve-Year Chronic Carriage Infection. MBio, 2013, 4, .	4.1	121
28	Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand. A position statement from the Thoracic Society of Australia and New Zealand and the Australian Lung Foundation. Medical Journal of Australia, 2010, 193, 356-365.	1.7	120
29	Pseudomonas aeruginosa Exhibits Frequent Recombination, but Only a Limited Association between Genotype and Ecological Setting. PLoS ONE, 2012, 7, e44199.	2.5	114
30	Clonal strains of Pseudomonas aeruginosa in paediatric and adult cystic fibrosis units. European Respiratory Journal, 2004, 24, 101-106.	6.7	113
31	A multinational report to characterise SARS-CoV-2 infection in people with cystic fibrosis. Journal of Cystic Fibrosis, 2020, 19, 355-358.	0.7	113
32	Identification of an unusual Brucella strain (BO2) from a lung biopsy in a 52 year-old patient with chronic destructive pneumonia. BMC Microbiology, 2010, 10, 23.	3.3	109
33	Indoor hospital air and the impact of ventilation on bioaerosols: a systematic review. Journal of Hospital Infection, 2019, 103, 175-184.	2.9	109
34	Importance of hepatic fibrosis in cystic fibrosis and the predictive value of liver biopsy. Hepatology, 2011, 53, 193-201.	7.3	103
35	Rapid genotyping of Pseudomonas aeruginosa isolates harboured by adult and paediatric patients with cystic fibrosis using repetitive-element-based PCR assays. Journal of Medical Microbiology, 2004, 53, 1089-1096.	1.8	102
36	Report of the European Respiratory Society/European Cystic Fibrosis Society task force on the care of adults with cystic fibrosis. European Respiratory Journal, 2016, 47, 420-428.	6.7	102

#	Article	IF	Citations
37	Phenotypic Characterization of Clonal and Nonclonal Pseudomonas aeruginosa Strains Isolated from Lungs of Adults with Cystic Fibrosis. Journal of Clinical Microbiology, 2007, 45, 1697-1704.	3.9	100
38	Resting energy expenditure and oxygen cost of breathing in patients with cystic fibrosis.. Thorax, 1996, 51, 126-131.	5.6	97
39	Identification of Pseudomonas aeruginosa by a duplex real-time polymerase chain reaction assay targeting the ecfX and the gyrB genes. Diagnostic Microbiology and Infectious Disease, 2009, 63, 127-131.	1.8	90
40	Effect of Temperature on Cystic Fibrosis Lung Disease and Infections: A Replicated Cohort Study. PLoS ONE, 2011, 6, e27784.	2.5	87
41	Reconstitution of the latent T-lymphocyte response to Epstein-Barr virus is coincident with long-term recovery from posttransplant lymphoma after adoptive immunotherapy. Transplantation, 2003, 75, 1556-1560.	1.0	86
42	Long term effects of denufosol tetrasodium in patients with cystic fibrosis. Journal of Cystic Fibrosis, 2012, 11, 539-549.	0.7	85
43	Antimicrobial susceptibility testing (AST) and associated clinical outcomes in individuals with cystic fibrosis: A systematic review. Journal of Cystic Fibrosis, 2019, 18, 236-243.	0.7	84
44	Management of comorbidities in older patients with cystic fibrosis. Lancet Respiratory Medicine,the, 2013, 1, 164-174.	10.7	83
45	Evidence for Spread of a Clonal Strain of Pseudomonas aeruginosa among Cystic Fibrosis Clinics. Journal of Clinical Microbiology, 2003, 41, 2266-2267.	3.9	81
46	Room ventilation and the risk of airborne infection transmission in 3Âhealth care settings within a large teaching hospital. American Journal of Infection Control, 2011, 39, 866-872.	2.3	81
47	Viability ofPseudomonas aeruginosain cough aerosols generated by persons with cystic fibrosis. Thorax, 2014, 69, 740-745.	5.6	79
48	Comparison of Three Molecular Techniques for Typing Pseudomonas aeruginosa Isolates in Sputum Samples from Patients with Cystic Fibrosis. Journal of Clinical Microbiology, 2011, 49, 263-268.	3.9	78
49	Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508delâ€CFTR. Annals of the American Thoracic Society, 2017, 14, 213-219.	3.2	78
50	Controlled longitudinal study of bone mass accrual in children and adolescents with cystic fibrosis. Thorax, 2006, 61, 146-154.	5.6	75
51	Beta-lactam allergy in adults with cystic fibrosis. Journal of Cystic Fibrosis, 2007, 6, 297-303.	0.7	74
52	Predictors of pulmonary exacerbations in patients with cystic fibrosis infected with multi-resistant bacteria. Thorax, 2006, 61, 969-974.	5.6	73
53	Screening bacterial metabolites for inhibitory effects against Batrachochytrium dendrobatidis using a spectrophotometric assay. Diseases of Aquatic Organisms, 2013, 103, 77-85.	1.0	73
54	Elevated metal concentrations in the CF airway correlate with cellular injury and disease severity. Journal of Cystic Fibrosis, 2014, 13, 289-295.	0.7	71

#	Article	IF	Citations
55	Pyrosequencing reveals transient cystic fibrosis lung microbiome changes with intravenous antibiotics. European Respiratory Journal, 2014, 44, 922-930.	6.7	71
56	Within-Host Evolution of Burkholderia pseudomallei during Chronic Infection of Seven Australasian Cystic Fibrosis Patients. MBio, 2017, 8, .	4.1	70
57	Metabolic and inflammatory responses to pulmonary exacerbation in adults with cystic fibrosis. European Journal of Clinical Investigation, 2000, 30, 553-559.	3.4	69
58	Rifampicin and sodium fusidate reduces the frequency of methicillin-resistant Staphylococcus aureus (MRSA) isolation in adults with cystic fibrosis and chronic MRSA infection. Journal of Hospital Infection, 2004, 56, 208-214.	2.9	66
59	Defining antimicrobial resistance in cystic fibrosis. Journal of Cystic Fibrosis, 2018, 17, 696-704.	0.7	66
60	Burkholderia pseudomallei: another emerging pathogen in cystic fibrosis. Thorax, 2003, 58, 1087-1091.	5.6	63
61	A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients. Journal of Cystic Fibrosis, 2015, 14, 507-514.	0.7	62
62	Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung Infections. Clinical Infectious Diseases, 2019, 69, 1812-1816.	5.8	62
63	Pseudomonas aeruginosa genotypes acquired by children with cystic fibrosis by age 5-years. Journal of Cystic Fibrosis, 2015, 14, 361-369.	0.7	61
64	SharedPseudomonas aeruginosagenotypes are common in Australian cystic fibrosis centres. European Respiratory Journal, 2013, 41, 1091-1100.	6.7	59
65	A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients. Journal of Cystic Fibrosis, 2016, 15, 495-502.	0.7	59
66	Mutations in ACTL6B Cause Neurodevelopmental Deficits and Epilepsy and Lead to Loss of Dendrites in Human Neurons. American Journal of Human Genetics, 2019, 104, 815-834.	6.2	59
67	Practical Guidelines: Lung Transplantation in Patients with Cystic Fibrosis. Pulmonary Medicine, 2014, 2014, 1-22.	1.9	58
68	Reduced Mucosal Associated Invariant T-Cells Are Associated with Increased Disease Severity and Pseudomonas aeruginosa Infection in Cystic Fibrosis. PLoS ONE, 2014, 9, e109891.	2.5	58
69	Abnormalities of the PTH-vitamin D axis and bone turnover markers in children, adolescents and adults with cystic fibrosis: comparison with healthy controls. Osteoporosis International, 2003, 14, 404-411.	3.1	57
70	Randomized Trial of a Decision Aid for Patients with Cystic Fibrosis Considering Lung Transplantation. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 761-768.	5.6	57
71	Inhaled steroids for bronchiectasis. The Cochrane Library, 2009, , CD000996.	2.8	57
72	CFTR-dependent defect in alternatively-activated macrophages in cystic fibrosis. Journal of Cystic Fibrosis, 2017, 16, 475-482.	0.7	57

#	Article	IF	Citations
73	Daily versus weekly azithromycin in cystic fibrosis patients. European Respiratory Journal, 2007, 30, 487-495.	6.7	55
74	Population Pharmacokinetics of Itraconazole and its Active Metabolite Hydroxy-Itraconazole in Paediatric Cystic Fibrosis and Bone Marrow Transplant Patients. Clinical Pharmacokinetics, 2006, 45, 1099-1114.	3.5	54
75	Gaming console exercise and cycle or treadmill exercise provide similar cardiovascular demand in adults with cystic fibrosis: a randomised cross-over trial. Journal of Physiotherapy, 2011, 57, 35-40.	1.7	53
76	Disruption of GRIN2B Impairs Differentiation in Human Neurons. Stem Cell Reports, 2018, 11, 183-196.	4.8	53
77	Low Rates of Pseudomonas aeruginosa Misidentification in Isolates from Cystic Fibrosis Patients. Journal of Clinical Microbiology, 2009, 47, 1503-1509.	3.9	52
78	Lesch-Nyhan Syndrome: Models, Theories, and Therapies. Molecular Syndromology, 2016, 7, 302-311.	0.8	52
79	Nutrition in adults with cystic fibrosis. Clinical Nutrition, 1998, 17, 211-215.	5.0	48
80	Face Masks and Cough Etiquette Reduce the Cough Aerosol Concentration of Pseudomonas aeruginosa in People with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 348-355.	5.6	48
81	Dissemination of Mycobacterium abscessus via global transmission networks. Nature Microbiology, 2021, 6, 1279-1288.	13.3	47
82	Geneâ€“environmental interaction in asthma. Current Opinion in Allergy and Clinical Immunology, 2007, 7, 75-82.	2.3	46
83	Transition of adolescents with cystic fibrosis from paediatric to adult care. Clinical Respiratory Journal, 2011, 5, 64-75.	1.6	46
84	Comparison of the US and Australian Cystic Fibrosis Registries: The Impact of Newborn Screening. Pediatrics, 2012, 129, e348-e355.	2.1	46
85	A d-optimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis patients. British Journal of Clinical Pharmacology, 2007, 63, 438-450.	2.4	45
86	Antibiotic desensitization in adults with cystic fibrosis. Respirology, 2003, 8, 359-364.	2.3	44
87	<scp>P</scp>seudomonas aeruginosa antibiotic resistance in <scp>A</scp>ustralian cystic fibrosis centres. Respirology, 2016, 21, 329-337.	2.3	43
88	Nutrition and survival in cystic fibrosis.. Thorax, 1996, 51, 971-972.	5.6	42
89	Pamidronate Results in Symptom Control of Hypertrophic Pulmonary Osteoarthropathy in Cystic Fibrosis. Chest, 2002, 121, 1363-1364.	0.8	42
90	Sputum neutrophils in cystic fibrosis patients display a reduced respiratory burst. Journal of Cystic Fibrosis, 2013, 12, 352-362.	0.7	42

#	Article	IF	Citations
91	The risk of airborne influenza transmission in passenger cars. Epidemiology and Infection, 2012, 140, 474-478.	2.1	41
92	Symptomatic and Asymptomatic Viral Recrudescence in Solid-Organ Transplant Recipients and Its Relationship with the Antigen-Specific CD8 ⁺ T-Cell Response. Journal of Virology, 2007, 81, 11538-11542.	3.4	40
93	Gene expression characteristics of a cystic fibrosis epidemic strain ofPseudomonas aeruginosaduring biofilm and planktonic growth. FEMS Microbiology Letters, 2009, 292, 107-114.	1.8	40
94	Cystic fibrosis in Australia, 2009: results from a data registry. Medical Journal of Australia, 2011, 195, 396-400.	1.7	40
95	Geographical Differences in First Acquisition of Pseudomonas aeruginosa in Cystic Fibrosis. Annals of the American Thoracic Society, 2013, 10, 108-114.	3.2	40
96	Implication of LRRC4C and DPP6 in neurodevelopmental disorders. American Journal of Medical Genetics, Part A, 2017, 173, 395-406.	1.2	40
97	Exacerbations in cystic fibrosis: 2 {middle dot} Prevention. Thorax, 2007, 62, 723-732.	5.6	38
98	CFTR activity is enhanced by the novel corrector GLPG2222, given with and without ivacaftor in two randomized trials. Journal of Cystic Fibrosis, 2019, 18, 700-707.	0.7	38
99	Nebulised dornase alpha: adherence in adults with cystic fibrosis. Journal of Cystic Fibrosis, 2002, 1, 255-259.	0.7	37
100	The role of anaerobic bacteria in the cystic fibrosis airway. Current Opinion in Pulmonary Medicine, 2016, 22, 637-643.	2.6	37
101	Vitamin A levels in patients with CF are influenced by the inflammatory response. Journal of Cystic Fibrosis, 2004, 3, 143-149.	0.7	36
102	A de novo frameshift mutation in chromodomain helicase DNAâ€binding domain 8 (CHD8): A case report and literature review. American Journal of Medical Genetics, Part A, 2016, 170, 1225-1235.	1.2	36
103	The changing prevalence of pulmonary infection in adults with cystic fibrosis: A longitudinal analysis. Journal of Cystic Fibrosis, 2017, 16, 70-77.	0.7	34
104	Face Masks Reduce the Release of Pseudomonas aeruginosa Cough Aerosols When Worn for Clinically Relevant Periods. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 1339-1342.	5.6	34
105	Pubertal development and its influences on bone mineral density in Australian children and adolescents with cystic fibrosis. Journal of Paediatrics and Child Health, 2005, 41, 317-322.	0.8	33
106	Factors Influencing Acquisition of Burkholderia cepacia Complex Organisms in Patients with Cystic Fibrosis. Journal of Clinical Microbiology, 2013, 51, 3975-3980.	3.9	33
107	Energy cost of physical activity in cystic fibrosis. European Journal of Clinical Nutrition, 2001, 55, 690-697.	2.9	32
108	Sub-inhibitory concentrations of ceftazidime and tobramycin reduce the quorum sensing signals of Pseudomonas aeruginosa. Pathology, 2004, 36, 571-575.	0.6	32

#	Article	IF	Citations
109	Within-host whole genome analysis of an antibiotic resistant Pseudomonas aeruginosa strain sub-type in cystic fibrosis. PLoS ONE, 2017, 12, e0172179.	2.5	31
110	Influence of climate variables on the rising incidence of nontuberculous mycobacterial (NTM) infections in Queensland, Australia 2001â€“2016. Science of the Total Environment, 2020, 740, 139796.	8.0	31
111	Inhaled Antibiotics in Cystic Fibrosis (CF) and Non-CF Bronchiectasis. Seminars in Respiratory and Critical Care Medicine, 2015, 36, 267-286.	2.1	30
112	Sources and dynamics of fluorescent particles in hospitals. Indoor Air, 2017, 27, 988-1000.	4.3	30
113	Transcriptomic analysis of longitudinal Burkholderia pseudomallei infecting the cystic fibrosis lung. Microbial Genomics, 2018, 4, .	2.0	30
114	Pregnancy and cystic fibrosis: Approach to contemporary management. Obstetric Medicine, 2014, 7, 147-155.	1.1	29
115	Protease IV production in Pseudomonas aeruginosa from the lungs of adults with cystic fibrosis. Journal of Medical Microbiology, 2006, 55, 1641-1644.	1.8	28
116	Antimicrobial treatment of non-cystic fibrosis bronchiectasis. Expert Review of Anti-Infective Therapy, 2014, 12, 1277-1296.	4.4	27
117	The social network of cystic fibrosis centre care and shared Pseudomonas aeruginosa strain infection: a cross-sectional analysis. Lancet Respiratory Medicine,the, 2015, 3, 640-650.	10.7	26
118	Lung function over the life course of paediatric and adult patients with cystic fibrosis from a large multi-centre registry. Scientific Reports, 2020, 10, 17421.	3.3	26
119	'Iron lung': Distinctive bronchoscopic features of acute iron tablet aspiration. Respirology, 2003, 8, 541-543.	2.3	25
120	Clonal complex Pseudomonas aeruginosa in horses. Veterinary Microbiology, 2011, 149, 508-512.	1.9	25
121	Pulmonary exacerbations in cystic fibrosis and bronchiectasis. Thorax, 2007, 62, 288-290.	5.6	24
122	Infection in cystic fibrosis: impact of the environment and climate. Expert Review of Respiratory Medicine, 2016, 10, 505-519.	2.5	24
123	Bronchiectasis: Treatment decisions for pulmonary exacerbations and their prevention. Respirology, 2018, 23, 1006-1022.	2.3	24
124	Antimicrobial resistance in cystic fibrosis: A Delphi approach to defining best practices. Journal of Cystic Fibrosis, 2020, 19, 370-375.	0.7	24
125	Macrolides in cystic fibrosis. Chronic Respiratory Disease, 2005, 2, 85-98.	2.4	23
126	An international, multicentre evaluation and description of Burkholderia pseudomallei infection in cystic fibrosis. BMC Pulmonary Medicine, 2015, 15, 116.	2.0	23

#	Article	IF	Citations
127	Non-invasive ventilation used as an adjunct to airway clearance treatments improves lung function during an acute exacerbation of cystic fibrosis: a randomised trial. Journal of Physiotherapy, 2015, 61, 142-147.	1.7	23
128	Cystic fibrosis pathogens survive for extended periods within cough-generated droplet nuclei. Thorax, 2019, 74, 87-90.	5.6	23
129	Differentiation of Human Induced Pluripotent Stem Cells (iPSCs) into an Effective Model of Forebrain Neural Progenitor Cells and Mature Neurons. Bio-protocol, 2019, 9, e3188.	0.4	22
130	Limitations to providing adult cystic fibrosis care in Europe: Results of a care centre survey. Journal of Cystic Fibrosis, 2017, 16, 85-88.	0.7	21
131	Expression of Pseudomonas aeruginosa Antibiotic Resistance Genes Varies Greatly during Infections in Cystic Fibrosis Patients. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	21
132	Aminoglycosides in cystic fibrosis: a descriptive study of current practice in Australia. Internal Medicine Journal, 2001, 31, 23-26.	0.8	20
133	A comparison of two informative SNP-based strategies for typing Pseudomonas aeruginosa isolates from patients with cystic fibrosis. BMC Infectious Diseases, 2014, 14, 307.	2.9	20
134	A Novel Method and Its Application to Measuring Pathogen Decay in Bioaerosols from Patients with Respiratory Disease. PLoS ONE, 2016, 11, e0158763.	2.5	20
135	Molecular Imprint of Exposure to Naturally Occurring Genetic Variants of Human Cytomegalovirus on the T cell Repertoire. Scientific Reports, 2014, 4, 3993.	3.3	19
136	Pulmonary artery enlargement and cystic fibrosis pulmonary exacerbations: a cohort study. Lancet Respiratory Medicine,the, 2016, 4, 636-645.	10.7	19
137	A Rapid Pipeline to Model Rare Neurodevelopmental Disorders with Simultaneous CRISPR/Cas9 Gene Editing. Stem Cells Translational Medicine, 2017, 6, 886-896.	3.3	19
138	Genomovar Diversity Amongst Burkholderia cepacia Complex Isolates From an Australian Adult Cystic Fibrosis Unit. European Journal of Clinical Microbiology and Infectious Diseases, 2003, 22, 434-437.	2.9	18
139	Burkholderia cepacia complex epidemiology in persons with cystic fibrosis from Australia and New Zealand. Research in Microbiology, 2008, 159, 194-199.	2.1	18
140	Death after Lung Transplantation in Cystic Fibrosis Patients Infected with Burkholderia cepacia. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 257-258.	5.6	18
141	Sexual and reproductive health in men with cystic fibrosis: Consistent preferences, inconsistent practices. Journal of Cystic Fibrosis, 2009, 8, 264-269.	0.7	18
142	High ambient temperature and risk of intestinal obstruction in cystic fibrosis. Journal of Paediatrics and Child Health, 2016, 52, 430-435.	0.8	18
143	Antimicrobial resistance in cystic fibrosis: Does it matter?. Journal of Cystic Fibrosis, 2018, 17, 687-689.	0.7	18
144	Anomalies in T Cell Function Are Associated With Individuals at Risk of Mycobacterium abscessus Complex Infection. Frontiers in Immunology, 2018, 9, 1319.	4.8	18

#	Article	IF	Citations
145	Human epididymis protein 4 (HE4) levels inversely correlate with lung function improvement (delta) Tj ETQq1 1 0.784314 rgBT /Overl 271-277.	0.7	18
146	Finding the relevance of antimicrobial stewardship for cystic fibrosis. Journal of Cystic Fibrosis, 2020, 19, 511-520.	0.7	18
147	The month of July: an early experience with pandemic influenza A (H1N1) in adults with cystic fibrosis. BMC Pulmonary Medicine, 2010, 10, 8.	2.0	17
148	Genotypic Diversity within a Single Pseudomonas aeruginosa Strain Commonly Shared by Australian Patients with Cystic Fibrosis. PLoS ONE, 2015, 10, e0144022.	2.5	17
149	Inhaled corticosteroids for bronchiectasis. The Cochrane Library, 2018, 5, CD000996.	2.8	17
150	Differential expression of genes and receptors in monocytes from patients with cystic fibrosis. Journal of Cystic Fibrosis, 2019, 18, 342-348.	0.7	17
151	Stimulation of L-type calcium channels increases tyrosine hydroxylase and dopamine in ventral midbrain cells induced from somatic cells. Stem Cells Translational Medicine, 2020, 9, 697-712.	3.3	17
152	Evidence for opioid modulation and generation of prostaglandins in sulphur dioxide (SO)2-induced bronchoconstriction.. Thorax, 1996, 51, 159-163.	5.6	16
153	Optimising nutrition in cystic fibrosis. Journal of Cystic Fibrosis, 2002, 1, 47-50.	0.7	16
154	Whole genome sequencing reveals the emergence of a Pseudomonas aeruginosa shared strain sub-lineage among patients treated within a single cystic fibrosis centre. BMC Genomics, 2018, 19, 644.	2.8	16
155	Genomic and phenotypic comparison of environmental and patient-derived isolates of Pseudomonas aeruginosa suggest that antimicrobial resistance is rare within the environment. Journal of Medical Microbiology, 2019, 68, 1591-1595.	1.8	16
156	Narrowing of Tâ€cell receptor beta variable repertoire during symptomatic herpesvirus infection in transplant patients. Immunology and Cell Biology, 2010, 88, 125-135.	2.3	15
157	Patient-reported outcomes in patients with cystic fibrosis with a G551D mutation on ivacaftor treatment: results from a cross-sectional study. BMC Pulmonary Medicine, 2019, 19, 146.	2.0	15
158	Nonâ€invasive ventilation versus oxygen therapy in cystic fibrosis: A 12â€month randomized trial. Respirology, 2019, 24, 1191-1197.	2.3	15
159	Intravenous aminoglycoside usage and monitoring of patients with cystic fibrosis in Australia. What's new?. Internal Medicine Journal, 2009, 39, 527-531.	0.8	14
160	Antimicrobial resistance: Concerns of healthcare providers and people with CF. Journal of Cystic Fibrosis, 2021, 20, 407-412.	0.7	13
161	Rapid single-nucleotide polymorphism-based identification of clonal Pseudomonas aeruginosa isolates from patients with cystic fibrosis by the use of real-time PCR and high-resolution melting curve analysis. Clinical Microbiology and Infection, 2011, 17, 1403-1408.	6.0	12
162	The treatment of the pulmonary and extrapulmonary manifestations of cystic fibrosis. Presse Medicale, 2017, 46, e139-e164.	1.9	12

#	Article	IF	Citations
163	Pathogen to commensal? Longitudinal within-host population dynamics, evolution, and adaptation during a chronic >16-year Burkholderia pseudomallei infection. PLoS Pathogens, 2020, 16, e1008298.	4.7	12
164	A Systematic Literature Review of Indoor Air Disinfection Techniques for Airborne Bacterial Respiratory Pathogens. International Journal of Environmental Research and Public Health, 2022, 19, 1197.	2.6	12
165	Tropical Australia is a potential reservoir of non-tuberculous mycobacteria in cystic fibrosis. European Respiratory Journal, 2017, 49, 1700046.	6.7	11
166	Effect of Nerve Stimulation Use on the Success Rate of Ultrasound-Guided Subsartorial Saphenous Nerve Block. Regional Anesthesia and Pain Medicine, 2017, 42, 25-31.	2.3	11
167	Antibiotic perturbation of mixed-strain Pseudomonas aeruginosa infection in patients with cystic fibrosis. BMC Pulmonary Medicine, 2017, 17, 138.	2.0	11
168	Multiâ€centre ethics and research governance review can impede nonâ€interventional clinical research. Internal Medicine Journal, 2019, 49, 722-728.	0.8	11
169	Lesch-Nyhan disease causes impaired energy metabolism and reduced developmental potential in midbrain dopaminergic cells. Stem Cell Reports, 2021, 16, 1749-1762.	4.8	11
170	Repeatability and methodology of resting energy expenditure in patients with cystic fibrosis. Respiration Physiology, 1999, 115, 301-307.	2.7	10
171	MRSA eradication in a health care worker with cystic fibrosis; re-emergence or re-infection?. Journal of Cystic Fibrosis, 2005, 4, 205-207.	0.7	10
172	Molecular surveillance for carbapenemase genes in carbapenem resistant Pseudomonas aeruginosa in Australian patients with cystic fibrosis. Pathology, 2015, 47, 156-160.	0.6	10
173	Whole-Genome Sequences of Five Burkholderia pseudomallei Isolates from Australian Cystic Fibrosis Patients. Genome Announcements, 2015, 3, .	0.8	10
174	Clostridium difficileinfection in cystic fibrosis: an uncommon but life-threatening complication. Respirology Case Reports, 2017, 5, e00204.	0.6	10
175	High-throughput single-nucleotide polymorphism-based typing of shared Pseudomonas aeruginosa strains in cystic fibrosis patients using the Sequenom iPLEX platform. Journal of Medical Microbiology, 2013, 62, 734-740.	1.8	9
176	Idiosyncratic reactions are the most common cause of abnormal liver function tests in patients with cystic fibrosis. Internal Medicine Journal, 2015, 45, 395-401.	0.8	9
177	Epidemiological Analysis of Methicillin-ResistantStaphylococcus aureusIsolates From Adult Patients With Cystic Fibrosis. Infection Control and Hospital Epidemiology, 2006, 27, 201-203.	1.8	8
178	Ivacaftor in severe cystic fibrosis lung disease and a <scp>G</scp> 551 <scp>D</scp> mutation. Respirology Case Reports, 2013, 1, 52-54.	0.6	8
179	Methicillin-resistant Staphylococcus aureus acquisition in healthcare workers with cystic fibrosis: a retrospective cross-sectional study. BMC Pulmonary Medicine, 2016, 16, 78.	2.0	8
180	The experience of men and women with cystic fibrosis who have become a parent: A qualitative study. Journal of Clinical Nursing, 2018, 27, 1702-1712.	3.0	8

#	Article	IF	Citations
181	A non-randomised single centre cohort study, comparing standard and modified bowel preparations, in adults with cystic fibrosis requiring colonoscopy. BMC Gastroenterology, 2019, 19, 89.	2.0	8
182	Cystic fibrosis â€“ Ten promising therapeutic approaches in the current era of care. Expert Opinion on Investigational Drugs, 2020, 29, 1107-1124.	4.1	8
183	Emergence and impact of oprD mutations in Pseudomonas aeruginosa strains in cystic fibrosis. Journal of Cystic Fibrosis, 2022, 21, e35-e43.	0.7	8
184	Quantitative real-time PCR assay for the rapid identification of the intrinsically multidrug-resistant bacterial pathogen Stenotrophomonas maltophilia. Microbial Genomics, 2019, 5, .	2.0	8
185	Clinical presentation of metabolic alkalosis in an adult patient with cystic fibrosis. Respirology, 2005, 10, 254-256.	2.3	7
186	Accurate assessment of systemic iron status in cystic fibrosis will avoid the hazards of inappropriate iron supplementation. Journal of Cystic Fibrosis, 2013, 12, 303-304.	0.7	7
187	Treatment decisions for MRSA in patients with cystic fibrosis (CF): when is enough, enough?. Thorax, 2017, 72, 297-299.	5.6	7
188	Work environment risks for health care workers with cystic fibrosis. Respirology, 2018, 23, 1190-1197.	2.3	7
189	Optimism, opportunities, outcomes: the Australian Cystic Fibrosis Data Registry. Internal Medicine Journal, 2018, 48, 721-723.	0.8	7
190	Sexual and reproductive health in cystic fibrosis. Current Opinion in Pulmonary Medicine, 2020, 26, 685-695.	2.6	7
191	Novel application of biological glue in the management of a complicated pneumothorax in cystic fibrosis. Pediatric Pulmonology, 2002, 34, 138-140.	2.0	6
192	Transmission of bacteria in bronchiectasis and chronic obstructive pulmonary disease: Low burden of cough aerosols. Respirology, 2019, 24, 980-987.	2.3	6
193	Mutations in the HFE gene can be associated with increased lung disease severity in cystic fibrosis. Gene, 2019, 683, 12-17.	2.2	6
194	Anti-inflammatory therapies in bronchiectasis. , 2011, , 223-238.		6
195	Genomic diversity and antimicrobial resistance of Prevotella species isolated from chronic lung disease airways. Microbial Genomics, 2022, 8, .	2.0	6
196	Can tumor necrosis factor-Î± (TNF-Î±) be reliably measured in blood?. Pediatric Pulmonology, 1995, 19, 226-230.	2.0	5
197	Exercise testing in patients with cystic fibrosis: Why and which?. Journal of Cystic Fibrosis, 2010, 9, 299-301.	0.7	5
198	Evaluation of phenotypic screening tests for carbapenemase production in Pseudomonas aeruginosa from patients with cystic fibrosis. Journal of Microbiological Methods, 2015, 111, 105-107.	1.6	5

#	Article	IF	Citations
199	JCF-2015. Journal of Cystic Fibrosis, 2016, 15, 1.	0.7	5
200	The Cystic Fibrosis Foundation Patient Registry. Design and Methods of a National Observational Disease Registry. Annals of the American Thoracic Society, 2016, 13, 1014-1015.	3.2	5
201	Lower airway microbiota for â€˜biomarkerâ€™ measurements of cystic fibrosis disease progression?. Thorax, 2018, 73, 1001-1003.	5.6	5
202	Prevention of chronic infection with Pseudomonas aeruginosa infection in cystic fibrosis. Current Opinion in Pulmonary Medicine, 2019, 25, 636-645.	2.6	5
203	Current infection control practices used in Australian and New Zealand cystic fibrosis centers. BMC Pulmonary Medicine, 2020, 20, 16.	2.0	5
204	Anti-LPS IgA and IgG Can Inhibit Serum Killing of Pseudomonas aeruginosa in Patients with Cystic Fibrosis. Infection and Immunity, 2021, 89, e0041221.	2.2	5
205	To the editor: On tumor necrosis factor Î± in CF. Pediatric Pulmonology, 1994, 17, 411-411.	2.0	4
206	Disruption in research publishing â€“ the open access revolution. Journal of Cystic Fibrosis, 2019, 18, 747-749.	0.7	4
207	Rapid macrolide and amikacin resistance testing for Mycobacterium abscessus in people with cystic fibrosis. Journal of Medical Microbiology, 2021, 70, .	1.8	4
208	Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Drug Treatment of Non-Tuberculous Mycobacteria in Cystic Fibrosis. Clinical Pharmacokinetics, 2021, 60, 1081-1102.	3.5	4
209	We are not doing enough to prevent the spread of COVIDâ€19 and other respiratory viruses in Australian hospitals. Medical Journal of Australia, 2021, 215, 152.	1.7	4
210	Express Yourself: Quantitative Real-Time PCR Assays for Rapid Chromosomal Antimicrobial Resistance Detection in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2022, 66, e0020422.	3.2	4
211	Prevalence of Complementary and Alternative Medicine Use by Adults with Cystic Fibrosis. Journal of Pharmacy Practice and Research, 2002, 32, 320-323.	0.8	3
212	A new phase of CFTR treatment for cystic fibrosis?. Lancet Respiratory Medicine,the, 2015, 3, 662-663.	10.7	3
213	Biomarkers: Their Role in CFTR Modulator Therapies from Early Development to the Clinic. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1375-1376.	5.6	3
214	Seven P's of publication practices. Journal of Cystic Fibrosis, 2020, 19, 333-335.	0.7	3
215	Redesign of the Australian Cystic Fibrosis Data Registry: A multidisciplinary collaboration. Paediatric Respiratory Reviews, 2021, 37, 37-43.	1.8	3
216	Prevention of SARS-CoV-2 (COVID-19) transmission in residential aged care using ultraviolet light (PETRA): a two-arm crossover randomised controlled trial protocol. BMC Infectious Diseases, 2021, 21, 967.	2.9	3

#	Article	IF	Citations
217	Integrative Therapies for People with Cystic Fibrosis. , 2012, , 113-126.		3
218	Duplex real-time PCR assay for the simultaneous detection of Achromobacter xylosoxidans and Achromobacter spp.. Microbial Genomics, 2020, 6, .	2.0	3
219	Differentiating Population Spatial Behavior Using Representative Features of Geospatial Mobility (ReFGeM). ACM Transactions on Spatial Algorithms and Systems, 2020, 6, 1-25.	1.4	3
220	CD161 expression defines new human Î³Î´ T cell subsets. Immunity and Ageing, 2022, 19, 11.	4.2	3
221	Pulmonary eosinophilia associated with aminoglutethimide. Australian and New Zealand Journal of Medicine, 1998, 28, 670-671.	0.5	2
222	Asthma care. Thorax, 2000, 55, 535-535.	5.6	2
223	Antibiotics in Chronic Obstructive Pulmonary Disease, Bronchiectasis and Cystic Fibrosis. , 0, , 389-413.		2
224	High prevalence of a class 1 integron-associated aadB gene cassette in Pseudomonas aeruginosa isolates from an Australian cystic fibrosis patient population. Pathology, 2008, 40, 524-525.	0.6	2
225	<scp>ICU</scp> outcomes in cystic fibrosis following invasive ventilation. Respirology, 2013, 18, 585-586.	2.3	2
226	Aztreonam for inhalation solution, challenges to drug approval and integration into CF care. Journal of Cystic Fibrosis, 2013, 12, 99-101.	0.7	2
227	Sugar sweet and deadly?. Microbiology (United Kingdom), 2009, 155, 665-666.	1.8	2
228	Emerging Nonpulmonary Complications for Adults With Cystic Fibrosis. Chest, 2022, 161, 1211-1224.	0.8	2
229	Cystic Fibrosis: A Disease in Transformation, yet More Work to Be Done!. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 487-489.	5.6	2
230	Neutrophil respiratory burst activity is not exaggerated in cystic fibrosis. Journal of Cystic Fibrosis, 2022, 21, 707-712.	0.7	2
231	Multidrug resistant tuberculosis. Thorax, 2001, 56, 980-980.	5.6	1
232	Has the time come to prescribe azithromycin in cystic fibrosis patients?. Internal Medicine Journal, 2005, 35, 73-74.	0.8	1
233	Superior vena cava obstruction due to total implantable venous access devices in cystic fibrosis: Case series and review. Respiratory Medicine CME, 2011, 4, 99-104.	0.1	1
234	The effect of CFTR modulation on the disease progression of cystic fibrosis in the era of precision medicine. Journal of Cystic Fibrosis, 2016, 15, e20.	0.7	1

#	Article	IF	Citations
235	Early Intervention of Cystic Fibrosis Pulmonary Exacerbations Based on Home Monitoring. eICE through the Looking Glass. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 1090-1092.	5.6	1
236	Reply to Zuckerman and Saiman: Use of Masks in Patients with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 1589-1590.	5.6	1
237	Benchmarking service provision, scope of practice, and skill mix for physiotherapists in adult cystic fibrosis care delivery. Physiotherapy Theory and Practice, 2020, , 1-7.	1.3	1
238	Treatment of pulmonary exacerbations in cystic fibrosis. Therapy: Open Access in Clinical Medicine, 2011, 8, 623-643.	0.2	1
239	An unusual intrabronchial foreign body in an asthmatic patient. Medical Journal of Australia, 1991, 154, 291-291.	1.7	1
240	Challenges of providing care to adults with cystic fibrosis. , 2014, , 286-303.		1
241	Trepopnoea due to positional narrowing of the left main bronchus. Australian and New Zealand Journal of Medicine, 1999, 29, 838-839.	0.5	0
242	Change in the Executive Editorial Team at JCF. Journal of Cystic Fibrosis, 2013, 12, 545-546.	0.7	0
243	JCF â€" 2014 and beyond. Journal of Cystic Fibrosis, 2014, 13, 610-611.	0.7	0
244	Cover Image, Volume 173A, Number 2, February 2017. American Journal of Medical Genetics, Part A, 2017, 173, i.	1.2	0
245	JCF â€“ 2016. Journal of Cystic Fibrosis, 2017, 16, 6.	0.7	0
246	Learningâ€™s from the Editors Desk â€“ 2017. Journal of Cystic Fibrosis, 2017, 16, 645-646.	0.7	0
247	Bronchiectasis: Yet another systemic disease?. Respirology, 2018, 23, 797-798.	2.3	0
248	Infection risks for patients from healthcare workers with cystic fibrosis â€•Reply. Respirology, 2019, 24, 393-394.	2.3	0
249	Abolition of Pseudomonas aeruginosa AUSTâ€01 from an Australian CF center: Do other strains remain?. Pediatric Pulmonology, 2019, 54, 515-516.	2.0	0
250	JCF â€“ progress in 2018. Journal of Cystic Fibrosis, 2019, 18, 1-5.	0.7	0
251	Reply: More on Causal Inference Studies. Annals of the American Thoracic Society, 2019, 16, 646-646.	3.2	0
252	Pursuit of Equity. Journal of Cystic Fibrosis, 2020, 19, 171.	0.7	0

#	Article	IF	Citations
253	Centralised versus outreach models of cystic fibrosis care should be tailored to the needs of the individual patient. Internal Medicine Journal, 2020, 50, 232-235.	0.8	0
254	Outcomes of artery embolisation for cystic fibrosis patients with haemoptysis: a 20â€year experience at a major Australian tertiary centre. Internal Medicine Journal, 2021, 51, 1526-1529.	0.8	0